Search clinical trials for: Licenced 4CMenB Vaccine

Total 6292 results

University of Adelaide
University of Sydney; The University of New South Wales; Menzies School of Health... and other collaborators

Recruiting

Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

Gonorrhea | Meningococcal Disease

Australia
University of Adelaide
SA Health

Completed

South Australian Meningococcal B Vaccine Herd Immunity Study (B Part of It)

Meningococcal Disease

Australia
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
St George's, University of London
GlaxoSmithKline; Public Health England; MeningitisNow

Completed

Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B (BEAR Men B)

Prematurity | Meningococcal Disease | Vaccination

United Kingdom
University of Oxford
KEMRI-Wellcome Trust Collaborative Research Program

Completed

Gonococcal Vaccine Study in Key Populations in Kenya (BexKPK)

Gonorrhea

Kenya
Chinese University of Hong Kong

Recruiting

Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Gonorrhea | Sexually Transmitted Infection

Hong Kong
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine (4CMenB)

Neisseria Gonorrhoeae Infection

United States
Mahidol University
World Health Organization; The Government Pharmaceutical Organization

Completed

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Influenza

Thailand
Kirby Institute
Griffith University

Active, not recruiting

Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)

Neisseria Gonorrheae Infection

Australia
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Ospedale Policlinico San Martino
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency (4CMenB)

Acquired Immunodeficiency

Italy
University of Melbourne

Completed

Influenza Vaccine in HIV Study

Influenza, Human
Mahidol University
The Government Pharmaceutical Organization

Recruiting

Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly

Influenza

Thailand
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Dengue Fever

Thailand
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
Novartis Vaccines

Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Meningococcal Disease | Meningococcal Meningitis

Spain, Brazil, Hungary, Peru
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
GlaxoSmithKline

Completed

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Meningitis, Meningococcal

Czechia
Pfizer

Completed

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Finland, Poland
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Seasonal Influenza

Philippines, Australia, Colombia, Argentina, Panama
National Institute of Allergy and Infectious Diseases...

Completed

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

HIV Infections

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Influenza

United States
JN-International Medical Corporation

Completed

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Meningococcal Infections | Meningococcal Meningitis

United States
Ology Bioservices

Completed

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Influenza

United States
Altimmune, Inc.
Optimal Health Research

Completed

Immune Response Following Seasonal Influenza Vaccination

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
GlaxoSmithKline

Completed

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Infections, Meningococcal

Germany, Canada, Australia, Belgium, Italy
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
Murdoch Childrens Research Institute
Brockhoff Foundation Australia; Shepherd Foundation Australia

Completed

Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination (HPV)

Cervical Cancer

Australia
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
BioNTech SE
Pfizer

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
Novartis Vaccines

Completed

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years

Pertussis | Whooping Cough | Tetanus | Diphtheria | Lockjaw

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Multisite Observational Maternal and Infant Study for COVID-19 (MOMI-Vax)

COVID-19

United States
GlaxoSmithKline

Completed

Safety of 4CMenB Exposure During Pregnancy

Infections, Meningococcal

United States

3

Subscribe